Peptidic diagnostic compositions
A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.
1. A diagnostic composition comprising:
the peptide of SEQ ID NO: 1, the peptide of SEQ ID NO: 2, or a peptide which is at least 80% identical to the peptide of SEQ ID NOs: 1 or 2, or a pharmaceutically acceptable salt or ester thereof;
a cysteine residue at the N-terminus of the peptide; and
at least one diagnostic molecule covalently attached to an amino group of the cysteine residue.
2. The diagnostic composition of claim 1 , wherein the diagnostic molecule is selected from: a compound that has at least one carbocyclic or heterocyclic ring or a linear carbon chain of at least three carbon atoms.
3. The diagnostic composition of claim 1 , wherein the diagnostic molecule is selected from: a photoactive molecule, a contrast agent, a chelating contrast agent, a ventilation contrast agent, and a radioactive molecule.
4. The diagnostic composition of claim 1 , further comprising a linker located between amino group of the cysteine residue and the diagnostic molecule.
5. The diagnostic composition of claim 1 , wherein the diagnostic molecule operates at either visible spectrum or near-infrared spectrum.
6. The diagnostic composition of claim 1 , wherein the diagnostic molecule is selected from: magnetic resonance contrast agent, an X-ray contrast media, a chelating contrast agent, a ventilation contrast agent, and a radioactive molecule.
7. The diagnostic composition of claim 3 , wherein the contrast agent molecule is selected from a paramagnetic molecule, a fluorinated molecule, a chemical exchange saturation transfer agent, and a paramagnetic chemical exchange saturation transfer agent.
8. A method of diagnosing a disease in a patient in need thereof, comprising delivering a diagnostic agent to a mammalian cell having a transferrin receptor (TFRC) or a receptor for advanced glycation end-product (RAGE) or both receptors, by administering an effective amount of the diagnostic composition of claim 1 to a patient in need thereof, and obtaining an image of a patient's body site containing said cell.
9. The method of claim 8 wherein the disease is selected from a central nervous system disorder, cancer, a cardiovascular disorder, an eye disorder, a gastrointestinal disorder, a lung disorder, a bone marrow disorder, a kidney disorder, a liver disorder, a spleen disorder, a pancreas disorder, a lymph node disorder, a lymphatic disorder, an adipose tissue disorder, and diabetes.
10. The diagnostic composition of claim 1 , wherein the peptide is SEQ ID NO: 2 or a peptide which is at least 80% identical to the peptide of SEQ ID NO: 2, or a pharmaceutically acceptable salt or ester thereof.
11. The method of claim 8 , wherein the peptide is SEQ ID NO: 2 or a peptide which is at least 80% identical to the peptide of SEQ ID NO: 2, or a pharmaceutically acceptable salt or ester thereof.